Brought to you by 
Tyco, CR Bard to merge; deal terminated
May 2001
Executive Summary
Tyco International had planned to acquire CR Bard (vascular, urological, and oncological diagnosis and intervention products) in a stock swap worth about $3.2bn, including the assumption of debt. However, since Tyco announced it will split into four independent companies, CR Bard and Tyco have mutually agreed to terminate their merger agreement. No break-up fees will be incurred.
Deal Industry
-
Medical Devices
- Diagnostic Equipment & Supplies
- Surgical Equipment & Devices
- Therapeutic Equipment & Devices
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tyco, CR Bard to merge; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice